January 2, 2008
Eurofins is happy to announce that - in line with its growth objectives - it has made four nominations to the Group Executive Committee (GEC). These appointments have been done in anticipation of the leadership needs resulting from the business expansion plans for the near future. Xavier Dennery, Luc Leroy and Jos Lamers will lead all or part of Eurofins’ Environmental, Pharma and Food testing businesses respectively. Arend Smit has taken charge of Eurofins corporate HR and leadership development programs. At the same time Wicher Wichers has chosen to become a non-executive director and Svend Aage Linde has left the GEC to focus fully on the development and integration of Eurofins laboratories in Scandinavia where the Group made substantial acquisitions recently. Furthermore Benoit Adelus left the Group at the end of 2007.
As stated in the Q1 2007 report, Xavier Dennery was appointed in April 2007 to the Group Executive Committee as Chief Executive for Eurofins Environment testing business. Mr Dennery had been with Eurofins for two years and was previously the Group’s Director for Southern Europe.
Since October 2007 Luc Leroy has been the new CEO of Eurofins Pharma Services, in charge of the Group’s laboratory network serving the pharmaceutical industry. He comes from SGS, most recently as their Managing Director for the UK and prior to that as their development director of Life Sciences in Belgium and France. Jos Lamers started at the beginning of December 2007 as the Regional President, leading the Group’s food testing operations in the Nordic, Benelux, British Isles and Southern European markets with the objective to grow Eurofins position in this region in line with Eurofins’ strategy. Jos spent 14 years at Numico. His last position was Director Metabolics, in charge of the worldwide metabolics business operations.
Arend Smit joined the Group Executive Committee in September and will combine his HR and leadership development tasks with responsibility for one of Eurofins development markets. Prior to joining Eurofins, Arend worked for Cadbury Schweppes as Managing Director for the Benelux and German markets. At the same time, the role of two of Eurofins long-standing Group Executive Committee members has evolved. Wicher Wichers has retired as leader of Eurofins Pharma activities and as a member of the Group Executive Committee. He will continue to sit on the Supervisory Board (Conseil d’Administration) as a non-executive director. As part of his new remit drs. Wichers will focus on a more strategic and advisory role and will be involved in specific development projects.
Similarly Svend Aage Linde, who stepped down from both the GEC and the Supervisory Board (Conseil d’Administration), will now concentrate on Eurofins significantly-growing activities in Scandinavia. In particular he has been key to the successful acquisition of Analycen and will continue to oversee the integration of that business.
Finally Eurofins announces that Benoit Adelus left the Group on December 31st, 2007 after successfully providing support to expand Eurofins leadership team at an important stage in the Group’s development. During that time he has also been the interim leader of part of the Group’s food business in Asia, UK and North America and has given Eurofins the benefit of his experience in many other areas. Gilles Martin, Eurofins CEO, commented “I would like to warmly thank Wicher, Svend Aage and Benoit for their contribution to Eurofins success. Their efforts and ideas were decisive in helping Eurofins become a leader in the markets where it operates, in defining Eurofins leadership charter which is at the core of Eurofins decentral entrepreneurial culture which favors empowerment of laboratory leaders, and in establishing a strong leadership team for the Group’s laboratories around the world”
For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: email@example.com
Notes for the editor: Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 7,000 staff in more than 100 laboratories across 27 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
Information réglementée :
Communiqués au titre de l'obligation d'information permanente
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIF||Euronext Paris||534.20 (c)||0.28%||14 509|